Positive surgical margin's impact on short-term oncological prognosis after robot-assisted partial nephrectomy (MARGINS study: UroCCR no 96).

Journal: Scientific reports
Published Date:

Abstract

The oncological impact of positive surgical margins (PSM) after robot-assisted partial nephrectomy (RAPN) is still under debate. We compared PSM and Negative Surgical Margins (NSM) in terms of recurrence-free survival (RFS), metastasis-free survival (MFS) and overall survival (OS) after RAPN, and we identified predictive factors of PSM. Multi-institutional study using the UroCCR database, which prospectively included 2166 RAPN between April 2010 and February 2021 (CNIL DR 2013-206; NCT03293563). Two groups were retrospectively compared: PSM versus NSM. Prognostic factors were assessed using Kaplan-Meyer curves with log-Rank test, cox hazard proportional risk model and logistic regression after univariate comparison. 136 patients had PSM (6.3%) and 2030 (93.7%) had NSM. During a median follow-up of 19 (9-36) months after RAPN, 160 (7.4%) recurrences were reported. Kaplan-Meier curves and analysis suggested that RFS, MFS and OS were not affected by a PSM (p = 0.68; 0.71; 0.88, respectively). In multivariate analysis predictors of PSM were a lower RENAL score (p = 0.001), longer warm ischemia time (WIT) (p = 0.003) and Chromophobe Renal Cell Carcinoma (chrRCC) (p = 0.043). This study found no impact of PSM on RFS, MFS or OS, and predictors of PSM were the RENAL score, WIT and chrRCC.

Authors

  • Arnoult Morrone
    Urology, Andrology, Renal Transplant Unit, Hôpital Pasteur 2, Nice University Hospital, Nice, France. arnoultmorrone@gmail.com.
  • Imad Bentellis
    Department of Urology, University of Nice, Nice, France.
  • Jean-Christophe Bernhard
    Department of Urology, University of Bordeaux, Bordeaux, France.
  • Karim Bensalah
    Department of Urology, Rennes University Hospital, 2, rue Henri Le Guilloux, 35033, Rennes Cedex, France.
  • Cécile Champy
    Department of Urology, Henri Mondor University Hospital, APHP, Paris, France.
  • Franck Bruyere
    Department of Urology, University of Tours, Tours, France.
  • Nicolas Doumerc
    Department of Urology, University of Toulouse, Toulouse, France.
  • Jonathan Olivier
    Department of Urology, Lille University and Regional Hospital, Lille, France.
  • François Audenet
    Department of Urology, AP-HP Centre, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France.
  • Bastien Parier
    Department of Urology, Hôpital Bicêtre, Université Paris Saclay, APHP, Le Kremlin-Bicêtre, France.
  • Martin Brenier
    Department of Urology, Paris Saint-Joseph Hospital Group, Paris, France.
  • Jean-Alexandre Long
    Urology Department, Grenoble University Hospital, Grenoble, France; TIMC-IMAG UMR CNRS 5525, Domaine de la Merci, La Tronche, France. Electronic address: JALong@chu-grenoble.fr.
  • François-Xavier Nouhaud
    Department of Urology, Rouen University Hospital, Rouen, France.
  • Nicolas Branger
    Department of Urology, Institut Paoli-Calmettes, Marseille, France.
  • Hervé Lang
    Department of Urology, Strasbourg University and Regional Hospital, Strasbourg, France.
  • Thomas Charles
    Department of Urology, Poitiers University Hospital, Poitiers, France.
  • Evanguelos Xylinas
    Department of Urology, Bichat-Claude Bernard Hospital, APHP, Paris Descartes University, Paris, France.
  • Thibaut Waeckel
    Department of Urology, Caen University Hospital, Caen, France.
  • Florie Gomez
    Department of Urology, Tenon Hospital, APHP, Paris, France.
  • Romain Boissier
    Department of Urology, Fundaciò Puigvert, Autonoma University of Barcelona, Barcelona, Spain. Romain.Boissier@ap-hm.fr.
  • Benjamin Rouget
    Department of Urology, Libourne Hospital, Libourne, France.
  • Aysha Shaikh
    Urology, Andrology, Renal Transplant Unit, Hôpital Pasteur 2, Nice University Hospital, Nice, France.
  • Daniel Chevallier
    Urology, Andrology, Renal Transplant Unit, Hôpital Pasteur 2, Nice University Hospital, Nice, France.
  • Damien Ambrosetti
    Central Laboratory of Pathology, Nice University Hospital, Nice, France.
  • Matthieu Durand
    Urology, Andrology, Renal Transplant Unit, Hôpital Pasteur 2, Nice University Hospital, Nice, France.